The
hospital infection therapeutics market was valued at USD 3.06 billion
in 2013 and is expected to grow at a CAGR of 3.1% from 2014 to 2020,
to reach an estimated value of USD 3.62 billion in 2020.
Browse
Hospital Infection Therapeutics Market Report with Full TOC at
http://www.transparencymarketresearch.com/hospital-infection-therapeutics.html
Hospital
infections, commonly known as hospital-acquired infections (HAIs) or
nosocomial infections, are referred to infections that develop in
patients undergoing treatment in a healthcare setting such as
hospitals, nursing homes, outpatient surgery centers, dialysis
centers and rehabilitation centers. According to the World Health
Organization (WHO), hospital infections are those infections that
occur within 48 hours of hospitalization or after 72 hours of
discharge from hospitals or within 30 days after treatment. Hospital
infections mostly originate in intensive care units (ICUs) of a
hospital compared to other divisions. According to the Centers for
Disease Control and Prevention (CDC), more than 1.7 million hospital
infections from different pathogenic microorganisms combined have
been reported in 2011, in the U.S. CDC also estimated that hospital
infections accounted for 99,000 deaths in the U.S. in the year 2011.
Major
hospital infection therapeutics that are available in the global
market has been categorized into three major drug segments, namely,
antibacterial, antiviral and antifungal drugs. Some of the major
types of hospital infections include hospital-acquired pneumonia,
urinary tract infections, gastrointestinal disorders, bloodstream
infections, surgical site infections and other hospital infections.
Request
for customization of this report
http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=1280
Major
driving factors for the growth of the hospital infection therapeutics
market include increasing prevalence of various hospital infections,
aging population, increasing healthcare awareness and demand for
improved therapeutic drugs. However, increasing multi-drug resistance
that has rendered many drugs obsolete and increasing number of
surveillance and infection control programs, such as, point
prevalence survey by ECDC, Europe and HAI prevalence survey by CDC,
U.S., may restrain the growth of this market. But, increasing
multi-drug resistance and demand for improved infection treatment
drugs have induced various drug developers and manufacturers to
develop advanced therapeutic drugs. Several drugs that are in their
phase III clinical trials will soon be commercialized during the
forecast period and will add to the growth of this market in future.
Some of the major drugs that are in their late stage clinical trials
are Ceftolozane/Tazobactam, Dalvance, Delafloxacin, MK-3415A,
Surotomycin, Eravacycline, and Tedizolid among others.
Browse
Press Release Hospital Infection Therapeutics Market
http://www.transparencymarketresearch.com/pressrelease/hospital-infection-therapeutics.htm
North
America dominates the global hospital infection therapeutics market,
in terms of revenue, followed by the European market in 2013. Major
factors responsible for the leading position of the North American
market are high prevalence of various hospital infections, rising
number of multidrug-resistant microbial pathogens, and increasing
demand for advanced therapeutics. High awareness level along with
high purchasing capacity of the people is also contributing to the
growth of the market in the region. Rising geriatric population in
North America and Europe will add to the population of affected
patients with hospital infections as aged patients exhibit lowered
immunity levels. Thus, the increase in affected patient population
will require increased use of various therapeutic drugs, which in
turn will contribute towards the growth of this market. Asia-Pacific
is expected to show the highest rate of growth in the global hospital
infection therapeutics market during the forecast period 2014 to
2020. Some of the major factors responsible for high growth rate are
rapidly increasing prevalence of hospital-acquired infections in the
region, rising awareness and demand for new and improved hospital
infection treatment drugs, and increasing healthcare infrastructure
as well as purchasing power of people in the region.
Actavis
plc, AstraZeneca plc, Bayer AG, Bristol-Myers Squibb Company, Cubist
Pharmaceuticals, Inc., GlaxoSmithKline plc, Johnson & Johnson
Services, Inc., Merck & Co., Inc., Pfizer, Inc., and Sanofi are
some of the major players operating in the global hospital infection
therapeutics market.
The
global hospital infection therapeutics market is segmented as
follows:
Hospital
Infection Therapeutics Market, by Drug Type
- Antibacterial Drugs
- Antiviral Drugs
- Antifungal Drugs
Hospital
Infection Therapeutics Market, by Major Infections
- Hospital-Acquired Pneumonia
- Surgical Site Infections
- Urinary Tract Infections
- Gastrointestinal Disorders
- Bloodstream Infections
- Other Hospital Infections
Hospital
Infection Therapeutics Market, by Geography
- North America
- Europe
- Asia-Pacific
- Rest of the World (RoW)
Browse
all Pharmaceutical Market Research Report
http://www.transparencymarketresearch.com/pharmaceutical-market-reports-1.htm
About
Us
Transparency
Market Research is a global market intelligence company, providing
global business information reports and services. Our exclusive blend
of quantitative forecasting and trends analysis provides
forward-looking insight for thousands of decision makers. We are
privileged with highly experienced team of Analysts, Researchers, and
Consultants, who use proprietary data sources and various tools and
techniques to gather, and analyze information.
Our
data repository is continuously updated and revised by a team of
research experts, so that it always reflects the latest trends and
information. With a broad research and analysis capability,
Transparency Market Research employs rigorous primary and secondary
research techniques in developing distinctive data sets and research
material for business reports.
Contact
Nachiket
State
Tower,
90
State Street,
Suite
700,
Albany
NY - 12207
United
States
USA
- Canada Toll Free: 866-552-3453
No comments:
Post a Comment